157 related articles for article (PubMed ID: 35227619)
1. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Schwarze JE; Venetis C; Iniesta S; Falla E; Lukyanov V; de Agustin Calvo E; D Hooghe T; Roeder C; Matorras R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):203-216. PubMed ID: 35227619
[TBL] [Abstract][Full Text] [Related]
2. Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.
Lehmann M; Arbo E; Pouly JL; Barrière P; Boland LA; Bean SG; Jenkins J
Eur J Obstet Gynecol Reprod Biol X; 2024 Jun; 22():100311. PubMed ID: 38741750
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.
Xue W; Lloyd A; Falla E; Roeder C; Papsch R; Bühler K
Int J Womens Health; 2019; 11():319-331. PubMed ID: 31191040
[No Abstract] [Full Text] [Related]
4. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ; Mol BW; Longobardi S; Orvieto R; Venetis CA; Lispi M; Storr A; D'Hooghe T
Reprod Biol Endocrinol; 2021 Apr; 19(1):51. PubMed ID: 33794909
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
Bühler K; Roeder C; Schwarze JE; Lispi M; Allignol A; Falla E; Lukyanov V; D Hooghe T; Fischer R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):188-202. PubMed ID: 35304097
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).
Grynberg M; Cedrin-Durnerin I; Raguideau F; Herquelot E; Luciani L; Porte F; Verpillat P; Helwig C; Schwarze JE; Paillet S; Castello-Bridoux C; D'Hooghe T; Benchaïb M
Best Pract Res Clin Obstet Gynaecol; 2023 Jun; 88():102308. PubMed ID: 36707343
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.
Gizzo S; Ferrando M; Lispi M; Ripellino C; Cataldo N; Bühler K
J Med Econ; 2018 Nov; 21(11):1096-1101. PubMed ID: 30113238
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars versus the originator of follitropin alfa: Randomized controlled trials are still the best way to evaluate their comparative effectiveness in assisted reproduction.
Venetis CA; Mol BW
Drug Discov Today; 2023 Feb; 28(2):103425. PubMed ID: 36332833
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective.
Matorras R; Chaudhari VS; Roeder C; Schwarze JE; Bühler K; Hwang K; Chang-Woo C; Iniesta S; D'Hooghe T; Mathur R
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102349. PubMed ID: 37327667
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
Saz-Parkinson Z; López-Cuadrado T; Bouza C; Amate JM
BioDrugs; 2009; 23(1):37-42. PubMed ID: 19344190
[TBL] [Abstract][Full Text] [Related]
14. Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions.
Manzi L; Sepe N; Migliaccio W; Lanzoni L; Iozzino L; D'Angelo F; Colarusso L; Montenegro S; Palmese A; D'Hooghe T; Ulloa-Aguirre A; Koloda Y; Lispi M
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743204
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.
Patel NH; Patel NH; Patel MN; Bhadarka HK; Vyas KS
J Hum Reprod Sci; 2023; 16(2):148-155. PubMed ID: 37547084
[TBL] [Abstract][Full Text] [Related]
16. Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.
Fragoulakis V; Pescott CP; Smeenk JM; van Santbrink EJ; Oosterhuis GJ; Broekmans FJ; Maniadakis N
Appl Health Econ Health Policy; 2016 Dec; 14(6):719-727. PubMed ID: 27581117
[TBL] [Abstract][Full Text] [Related]
17. Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization.
Bergandi L; Canosa S; Carosso AR; Paschero C; Gennarelli G; Silvagno F; Benedetto C; Revelli A
Pharmaceuticals (Basel); 2020 Jun; 13(7):. PubMed ID: 32605133
[TBL] [Abstract][Full Text] [Related]
18. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility.
Gizzo S; Garcia-Velasco JA; Heiman F; Ripellino C; Bühler K
Int J Womens Health; 2016; 8():683-689. PubMed ID: 27994486
[TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
